# Ramucirumab Plus Pembrolizumab vs Usual Care for Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer Following Immunotherapy, Pragmatica-Lung Study

> **NCT05633602** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **SWOG Cancer Research Network** · enrollment: 838 (actual)

## Conditions studied

- Recurrent Lung Non-Small Cell Carcinoma
- Stage IV Lung Cancer AJCC v8

## Interventions

- **DRUG:** Chemotherapy
- **BIOLOGICAL:** Pembrolizumab
- **BIOLOGICAL:** Ramucirumab

## Key facts

- **NCT ID:** NCT05633602
- **Lead sponsor:** SWOG Cancer Research Network
- **Sponsor class:** NETWORK
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-03-14
- **Primary completion:** 2025-11-26
- **Final completion:** 2028-03-15
- **Target enrollment:** 838 (ACTUAL)
- **Last updated:** 2026-04-17

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05633602

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05633602, "Ramucirumab Plus Pembrolizumab vs Usual Care for Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer Following Immunotherapy, Pragmatica-Lung Study". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05633602. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*